Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

Similar articles for PubMed (Select 24477463)

1.

[Disease modification and duration of omalizumab treatment in patients with severe allergic asthma].

Schreiber J, Kopp MV, Korn S, Taube C, Buhl R.

Pneumologie. 2014 Mar;68(3):187-92. doi: 10.1055/s-0033-1359242. Epub 2014 Jan 29. Review. German.

PMID:
24477463
2.

Omalizumab for asthma in adults and children.

Normansell R, Walker S, Milan SJ, Walters EH, Nair P.

Cochrane Database Syst Rev. 2014 Jan 13;1:CD003559. doi: 10.1002/14651858.CD003559.pub4. Review.

PMID:
24414989
3.

Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.

Somerville L, Bardelas J, Viegas A, D'Andrea P, Blogg M, Peachey G.

Curr Med Res Opin. 2014 Jan;30(1):59-66. doi: 10.1185/03007995.2013.844115. Epub 2013 Oct 1.

PMID:
24028677
4.

Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents.

Steiss JO, Schmidt A, Nährlich L, Zimmer KP, Rudloff S.

Allergy Asthma Proc. 2012 Jan-Feb;33(1):77-81. doi: 10.2500/aap.2012.33.3500.

PMID:
22370532
5.

Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.

Özgür ES, Özge C, Ïlvan A, Naycı SA.

J Asthma. 2013 Aug;50(6):687-94. doi: 10.3109/02770903.2013.792348. Epub 2013 May 9.

PMID:
23557459
6.

Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey.

Deschildre A, Marguet C, Salleron J, Pin I, Rittié JL, Derelle J, Taam RA, Fayon M, Brouard J, Dubus JC, Siret D, Weiss L, Pouessel G, Beghin L, Just J.

Eur Respir J. 2013 Nov;42(5):1224-33. doi: 10.1183/09031936.00149812. Epub 2013 Mar 21.

7.

Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel.

Rottem M.

J Asthma. 2012 Feb;49(1):78-82. doi: 10.3109/02770903.2011.637598. Epub 2011 Dec 7.

PMID:
22149205
8.

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P.

Pediatrics. 2001 Aug;108(2):E36.

PMID:
11483846
9.

Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table.

Kornmann O, Watz H, Fuhr R, Krug N, Erpenbeck VJ, Kaiser G.

Pulm Pharmacol Ther. 2014 Aug;28(2):149-53. doi: 10.1016/j.pupt.2014.03.003. Epub 2014 Mar 18.

10.

Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.

Chipps BE, Figliomeni M, Spector S.

Allergy Asthma Proc. 2012 Sep-Oct;33(5):377-85. doi: 10.2500/aap.2012.33.3599.

PMID:
23026179
11.

Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.

Dal Negro RW, Guerriero M, Micheletto C, Tognella S, Visconti M.

J Asthma. 2011 Jun;48(5):437-41. doi: 10.3109/02770903.2011.578316.

PMID:
21599560
12.

A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.

D'Amato G, Piccolo A, Salzillo A, Noschese P, D'Amato M, Liccardi G.

Recent Pat Inflamm Allergy Drug Discov. 2007 Nov;1(3):225-31. Review.

PMID:
19075985
13.

[Omalizumab therapy in adolescents with severe allergic asthma - results of a post-marketing surveillance].

Klyucheva M, von Berg A, Gappa M, Suerbaum C, Berdel D.

Pneumologie. 2013 Apr;67(4):233-7. doi: 10.1055/s-0032-1326356. Epub 2013 Apr 10. German.

PMID:
23576201
14.

Monitoring free serum IgE in severe asthma patients treated with omalizumab.

Korn S, Haasler I, Fliedner F, Becher G, Strohner P, Staatz A, Taube C, Buhl R.

Respir Med. 2012 Nov;106(11):1494-500. doi: 10.1016/j.rmed.2012.07.010. Epub 2012 Aug 11.

15.

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.

Djukanović R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Matthews J, Busse WW, Holgate ST, Fahy JV.

Am J Respir Crit Care Med. 2004 Sep 15;170(6):583-93. Epub 2004 Jun 1.

PMID:
15172898
16.

Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.

Zhu R, Zheng Y, Putnam WS, Visich J, Eisner MD, Matthews JG, Rosen KE, D'Argenio DZ.

AAPS J. 2013 Apr;15(2):559-70. doi: 10.1208/s12248-013-9463-9. Epub 2013 Feb 15.

17.

Anti-IgE for chronic asthma in adults and children.

Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003559. Review. Update in: Cochrane Database Syst Rev. 2014;1:CD003559.

PMID:
16625585
18.

Plasmapheresis prior to omalizumab administration in a 15-year-old boy with severe asthma and very high IgE levels: sustained effect over 2 years.

Kerzel S, Zemlin M, Rogosch T, Ollert M, Renz H, Klaus G, Maier RF.

Klin Padiatr. 2011 Nov;223(6):356-9. doi: 10.1055/s-0031-1287824. Epub 2011 Oct 19.

PMID:
22012605
19.

Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation.

Macglashan DW Jr, Saini SS.

J Allergy Clin Immunol. 2013 Oct;132(4):906-11.e1-4. doi: 10.1016/j.jaci.2013.04.056. Epub 2013 Jun 20.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk